A study of TAK-279 for Crohn's disease
Part of Digestive system clinical trials.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old (19 or older in South Korea).
- You have been diagnosed with Crohn's disease for at least 30 days and it is moderately to severely active.
- You have tried at least one earlier treatment (like a biologic or other advanced therapy) that didn't work or caused side effects.
- You do not have a current ostomy or other types of colitis (like ulcerative colitis).
- You have not already failed 3 or more different types of advanced therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests a new medicine called SL-325, which may help reduce inflammation in the gut. It is for people with moderate to severe Crohn's disease who have not responded well to other treatments.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.